News | Artificial Intelligence | July 17, 2024

The total number of Hyperfine AI-powered marketing authorizations places the company in a leading position on recently published FDA list

The total number of Hyperfine AI-powered marketing authorizations places the company in a leading position on recently published FDA list

July 17, 2024 — Hyperfine, a groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance brain imaging system—the Swoop system—announced the clearance of the ninth generation of AI-powered Swoop system software. This advanced software significantly reduces scan times across multiple MR sequences without sacrificing image quality. The U.S. Food and Drug Administration (FDA) clearance of this software further solidifies Hyperfine as a leader in AI-powered health technology.

These scan time reductions may enable Swoop system images to help speed up the diagnostic process in acute care settings, which is crucial for time-sensitive medical conditions such as stroke, where every second counts. Reducing the overall acquisition time for sequences can also decrease the negative impact of patient motion on image quality.

Professor Adnan Siddiqui, MD, PhD, from the University of Buffalo, emphasized the impact of rapid imaging capabilities, saying, “Timely MR brain imaging is essential for clinicians making critical treatment decisions, particularly in acute neurological episodes like strokes. We have been an active site in the ACTION PMR study assessing the use of the Swoop system in stroke diagnosis, and this latest software will help the Swoop system more seamlessly integrate into stroke workflows. It is wonderful to see Hyperfine respond quickly to clinical feedback and continue to innovate to improve the Swoop system.”

The total number of Hyperfine AI-powered marketing authorizations places the company in a leading position on the FDA’s Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices list, underscoring the commitment of Hyperfine to leveraging AI to advance ultra-low-field portable MR brain imaging technology and improve patient care.

“With the release of our ninth-generation AI-powered software, we continue to broaden the clinical utility and workflow fit of the Swoop system,” said Tom Teisseyre, Chief Operating Officer at Hyperfine. “The balance between speed and image quality is crucial in acute care settings where early and timely information is essential to inform the best decisions for patients. We’re proud of every step we’ve taken with the Swoop system, learning from and responding to our user base and the broader medical community.

For more information: www.hyperfine.io


Related Content

News | Cardiac Imaging

July 8, 2026 — Conavi Medical Corp. has announced the publication of a case report in the Journal of the Society for ...

Time July 15, 2026
arrow
News | PET Imaging

July 14, 2026 — New research is shedding new light on the biological basis of schizophrenia by directly measuring ...

Time July 15, 2026
arrow
News | Neuro Imaging

July 9, 2026 — Viz.ai has announced a collaboration with Cortechs.ai to integrate Cortechs.ai's NeuroQuant and ...

Time July 10, 2026
arrow
News | Ultrasound Imaging

July 7, 2026 — Longeviti Neuro Solutions has launched a new strategic initiative, ClearFit AI, a Brain Ultrasound ...

Time July 09, 2026
arrow
News | Prostate Cancer

July 8,2026 — CorePlus, Puerto Rico’s fully digital precision pathology and clinical laboratory, has announced the ...

Time July 08, 2026
arrow
News | Breast Imaging

July 7, 2026 — QT Imaging Holdings, Inc. recently announced it has successfully completed its first routine inspection ...

Time July 07, 2026
arrow
News | MRI Breast

July 2, 2026 – Quibim has announced the European and UK launch of QP-Breast, its CE and UKCA-marked AI tool which ...

Time July 02, 2026
arrow
News | Women's Health

July 1, 2026 — Despite declining birth rates worldwide, the complexity of pregnancy is increasing. Advanced maternal age ...

Time July 01, 2026
arrow
News | Mammography

June 30, 2026 — The Food and Drug Administration has cleared new contrast-enhanced mammography (CEM) and CEM biopsy ...

Time June 30, 2026
arrow
News | Information Technology

June 26, 2026 — Radin Health recently announced the successful deployment of its cloud-native platform at four ...

Time June 26, 2026
arrow
Subscribe Now